

## Editorial

# Estrogen Deficiency and Bone Remodeling

**Renata Falchete do Prado\***

Department of Physiotherapy, Cruzeiro Superior School – ESC, Cruzeiro, São Paulo, Brazil

\***Corresponding author:** Renata Falchete do Prado, Department of Physiotherapy, Cruzeiro Superior School – ESC, Cruzeiro, São Paulo, Brazil

**Received:** July 09, 2014; **Accepted:** July 15, 2014;

**Published:** July 15, 2014

## Editorial

Bone is a dynamic tissue, lying in a constant process of remodeling [1]. Bone remodeling plays a fundamental role in the homeostasis of calcium serum levels [2]. In post-menopausal osteoporosis, resorption is increased when comparing to bone apposition. Consequently there is bone loss [3].

The mechanisms linking estrogen and the regulation of bone remodeling are still unknown [4], however, *in vitro* studies suggest that this hormone acts on secretion and activity of the factors that regulate osteoblast precursors and prevent osteoclast formation [5]. Estrogen receptors of osteoblasts and osteoclasts have regulatory functions in these cells and consequently in bone remodeling [1].

Osteoblasts exert their physiological signaling function mediating osteoclastic resorption when its activation occurs by inducers such as parathyroid hormone (PTH), interleukin 1 (IL-1), tumor necrosis factor (TNF) or prostaglandin (PGE-2), which stimulate osteoblasts to secrete factors that induce osteoclasts to resorb bone. The decrease in estrogen levels results in increased production cytokines involved in bone reabsorption [6].

Hughes et al. [7] investigated *in vitro* and *in vivo* the estrogenic function in the regulation of osteoclasts apoptosis. According to the authors, estrogen increases the production of TGF- $\beta$  by osteoclasts. The anti-TGF- $\beta$  antibody reduces apoptosis of osteoclasts. Thus, estrogens may regulate resorption, limiting osteoclasts life.

Estrogen has appreciable effect on the expression of cytokines and growth factors by osteoblasts and osteoclasts, which play an important role in its paracrine and autocrine action. Some growth factors which can act in signaling, proliferation, migration and matrix synthesis by osteoblasts are: platelet derived growth factor (PDGF), insulin-like growth factors (IGF) I and II, fibroblast growth factor (FGF), transforming growth factor (TGF), especially TGF- $\beta$  and bone morphogenetic proteins (BMPs). Among these growth factors, the main related to estrogen are: IGF-I and II, TGF- $\beta$  and PDGF [8].

The IGF I and II can stimulate mitosis and collagen synthesis in osteoblasts, while TGF- $\beta$  displays dual effect, stimulating or depressing the osteogenic function. FGF and PDGF have similar functions, but with secondary importance.

The IGF also promotes the synthesis of cartilage matrix.

Chondrocytes secrete IGF and react to this factor in an autocrine signaling pathway. Its role in bone remodeling and repair is not completely understood [9]. However, Okazaki et al. [10] believe that the inflammatory chemical mediators, such as prostaglandins, secreted after a trauma can induce the expression of IGF-I. In the early periods of repair, messenger ribonucleic acid (mRNA) of IGF-I was expressed by mesenchymal cells, immature chondrocytes, pre-osteoblasts, osteoblasts and osteocytes in bone callus. After two weeks of repair, osteoblasts continue to express IGF-I. This factor seems to be involved in the proliferation and differentiation of osteoblasts and chondrocytes, acting as an autocrine and paracrine mitogenic factor during bone repair.

Despite being found in lesser amounts compared to IGF-II, IGF-I promotes increased collagen synthesis, being more active on bone tissue [11].

With respect to the functions of TGF-beta, according Finkelman et al. [12] the deficiency of this factor in ovariectomized rats bone, suggest its importance in maintenance of bone volume, since it can induce proliferation and differentiation of bone cells [11].

Another route of action of estrogens on bone remodeling signaling is osteoprotegerin (OPG), receptor activator of NF- $\kappa$ B (RANK) and RANK cytokine ligand (RANKL), identified as the major factors involved in osteoclastogenesis. RANK is located on the surface of mature osteoclasts and their precursors, while RANKL is a protein that belongs to the tumor necrosis factor (TNF) family. Its main role is to inhibit apoptosis of osteoclasts and stimulate the differentiation and activation of these cells. OPG directly inhibit the binding RANKL with RANK. Its effects are antagonistic to the effects of RANKL.

Several cytokines and compounds such as estrogens affect osteoclastogenesis by regulating the production of RANKL/OPG by stromal cells and osteoblasts [13]. Subsequently menopause, bone loss arises because the RANKL action is favored above the OPG. Decrease of the estrogen levels reduces the OPG activity and improves the RANKL activity, resulting in increased resorption and bone loss.

Steeve et al. [13] reported that both estrogen and TGF- $\beta$  increase OPG production, consequently decreasing the differentiation and activation of osteoclasts, as well as inducing apoptosis of these cells.

An experimental model that mimics estrogen deficiency in postmenopausal women is ovariectomy in rats, which results in decreased levels of estrogen [14]. As a result, ovariectomy causes bone loss. Despite differences between women and experimental animals, this model is considered appropriate to study osteopenia in estrogen deficiency [15]. An option is the excision of testicles in male rats, but this type of study is less used than ovariectomy.

Avoid weight gain in ovariectomized animals is necessary because this, could be a protecting mechanism [16,17], which use the fat as a source of estrogenic hormones, and may alter bone loss desired in the study model since bone, mammary glands, placenta and adipose

tissue express the aromatase enzyme involved in the synthesis of estrogens [18]

New knowledge that can guide the therapeutic management of women with postmenopausal osteoporosis, can contribute in improving the quality of life of these patients. New studies that attempt to better understand the mechanisms of regulation of bone remodeling by estrogens are essential.

## References

1. Lerner UH. Bone remodeling in post-menopausal osteoporosis. *Journal of Dental Research* 2006; 85: 584-595.
2. Hadjidakis DJ, Androulakis II. Bone remodeling. *Women's Health and Disease: Gynecologic, Endocrine, and Reproductive Issues* 2006; 1092: 385-396.
3. Robling AG, Castillo AB, Turner CH Biomechanical and molecular regulation of bone remodeling. *Annu Rev Biomed Eng.* 2006; 8: 455-498.
4. Raisz LG. Physiology and pathophysiology of bone remodeling. *Clinical Chemistry* 1999;45: 1885-1885.
5. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. *Journal of Biological Chemistry* 2001; 276: 8836-8840.
6. Horowitz MC Cytokines and estrogen in bone: anti-osteoporotic effects. *Science.* 1993; 260: 626-627.
7. Hughes DE, Dai A, Tiffée JC, Li HH, Mundy GR, Boyce BF Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. *Nat Med.* 1996; 2: 1132-1136.
8. Turner RT, Riggs BL, Spelsberg TC Skeletal effects of estrogen. *Endocr Rev.* 1994; 15: 275-300.
9. Hollinger J, Wong ME The integrated processes of hard tissue regeneration with special emphasis on fracture healing. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1996; 82: 594-606.
10. Okazaki K, Jingushi S, Ikenoue T, Urabe K, Sakai H, Iwamoto Y Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. *J Orthop Res.* 2003; 21: 511-520.
11. Seino Y Cytokines and growth factors which regulate bone cell function. *Acta Astronaut.* 1994; 33: 131-136.
12. Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss. *Proc Natl Acad Sci U S A.* 1992; 89: 12190-12193.
13. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. *Cytokine & Growth Factor Reviews* 2004;15: 49-60.
14. Sims NA, Morris HA, Moore RJ, Durbridge TC Estradiol treatment transiently increases trabecular bone volume in ovariectomized rats. *Bone.* 1996; 19: 455-461.
15. Kalu DN The ovariectomized rat model of postmenopausal bone loss. *Bone Miner.* 1991; 15: 175-191.
16. Harrison E, Adjei A, Ameho C, Yamamoto S, Kono S The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. *J Nutr Sci Vitaminol (Tokyo).* 1998; 44: 257-268.
17. Wronski TJ, Schenck PA, Cintrón M, Walsh CC Effect of body weight on osteopenia in ovariectomized rats. *Calcif Tissue Int.* 1987; 40: 155-159.
18. Conley A, Hinshelwood M Mammalian aromatases. *Reproduction.* 2001; 121: 685-695.